$5.8 Million has been invested in the company to date. Seeking a minimum of $5 million and up to $30M at an estimated ~$50 million pre-money valuation. Funds will be used to bring the first products to market.
Company is 60% owned by founders/management. Remaining by a diverse group of shareholders
Exit timeline. Liquidity outlook
Company via an exit through the sale of the firm to a large pharma company or through an IPO, the occurrence of which is anticipated by 2019.
We have a 10 x on the company at the current valuation if successful.